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Abstract
Introduction: Papulopruritic eruption (PPE) occurs in people living with HIV in India. Understanding the risk factors associated
with this disease may help decrease the prevalence of PPE.
Methods: This study was a case-control study performed at the Government Hospital of Thoracic Medicine, a tertiary care
hospital in Chennai, India. Cases included HIV-positive, antiretroviral (ARV) therapy-naı ¨ve adults experiencing a pruritic skin
eruption for longer than one month, with evidence of multiple papular or nodular lesions and biopsy consistent with arthropod
bite. Controls included HIV-positive, ARV-naı ¨ve patients without active skin rash. Main outcome measures were CD4 cell count,
histology, and environmental exposures. We performed statistical analysis using Epi Info version 3.5.1 and SPSS version 11.0
(SPSS Inc., Chicago, IL). Categorical variables such as gender, urban versus rural residence, occupation, treatment history, CD4
count, use of insect repellents, and environmental exposures were evaluated using the x
2 test (or the Fisher exact test when an
expected value for a category was less than 5). The t-test was used to evaluate differences in age and the duration since HIV
diagnosis. The Mann-Whitney test was used to compare non-normally distributed values such as CD4 cell count. A p-value that
was less than 0.05 was considered to be statistically significant.
Results: Forty-one cases and 149 control subjects were included. Subjects with PPE had significantly lower CD4 cell counts
compared to controls (225.5 cells/mL vs. 425 cells/mL; p0.0001). Sixty-six percent of cases had a CD4 cell count less than 350
cells/mL. PPE cases were less likely to use mosquito repellent techniques (odds ratio 2.81, CI 1.455.45).
Discussion: PPE may be an alteredand exaggerated immune response to arthropod bites in HIV-positive patients.CD4 cell count is
significantly lower in patients with PPE, and therefore it may be considered a qualifying clinical finding for ARV initiation in
resource-poorsettings. Protectivemeasuresagainstmosquito bites appearedto beimportantinpreventing PPE insubjects atrisk.
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Introduction
‘‘Papulopruritic eruption’’ (PPE) of HIV is a major cause of
morbidity in AIDS patients in Asia. It is a commonly occurring,
intensely pruritic, and stigmatizing skin rash that is reported
to occur in 1246% of patients with HIV infection, varying by
geographic location [14]. In patients with PPE, average CD4
counts have been reported to range between 46 and 165
cells/mL [3,511]. Beginning in 1983, studies from African
countries [1,2,1216], India [8,17], Thailand [18,19], China
[20], and Brazil [9] described an extremely pruritic, diffuse
skin eruption occurring in HIV-positive patients. The primary
lesion for PPE is a firm, discrete, erythematous, urticarial
papule or pustule originating on the extremities and
occasionally evolving onto the trunk [3]. Most patients
scratch the lesions because of the severe pruritus, leading
to excoriated papules, marked postinflammatory pigment
changes, and, eventually, prurigo-like nodules. The persistent
pruritus is usually refractory to topical steroids and oral
antihistamines [13]. However, in a group of patients with
PPE, pruritus decreased with the use of antiretroviral (ARV)
therapy within a 16-week period [6].
A study from Uganda showed that PPE was histologically
consistent with arthropod bites. Whether PPE is due to an
actual insect bite or a reaction process that histologically
mimics an arthropod bite is unclear. This histologic reaction
pattern may also be observed in lymphomatous malignant
processes, as well as benign pseudolymphomatous disorders,
which may occur in response to various factors, including
insect bites and medications. Ultimately, if a lymphomatous
process is being entertained, proper histological stains should
be performed to help rule out malignant processes. Although
mechanisms of disease were not directly demonstrated, PPE
is thought to be a hypersensitivity reaction to arthropod bites
and is associated with immunodeficiency [7,21].
HIV surveillance in India estimates that the national HIV
prevalence is 0.36% (0.300.50%), with the majority of
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1infections concentrated in high-risk populations such as
commercial sex workers, men who have sex with men, and
intravenous drug users.The geographic burden of the disease
is reported to be heterogeneous, with HIV prevalence highest
in the southern and northeastern states, ranging from 0.03%
inHimachalPradeshto1.67%inManipur[22].Commonpapu-
lar eruptions specific to HIV-positive individuals include PPE
and eosinophilic folliculitis (EF). Clinically, these disorders are
difficult to distinguish from one another, as they both consist
of extremely pruritic generalized papules and pustules invol-
ving the face, trunk, and extremities. Histopathologic exami-
nation may help aid in the differentiation of PPE from EF by
examination of serial sections, which demonstrate normal
pilosebaceous units with a lymphocytic- and eosinophilic-rich
perivascular infiltrate in the former, in comparison to a
folliculocentric lymphocytic and eosinophilic infiltrate in the
latter [7,21]. In addition, EF histopathologically demonstrates
spongiosis of the follicular epithelium, with the infiltrate
concentrated near the follicular isthmus and sebaceous duct.
Another histopathological comparison may include suppura-
tive folliculitis. In this disorder, neutrophils and macrophages
predominate in the infiltrate, and microorganisms are readily
found in the inflammatory reaction. Involved follicles in
suppurative folliculitis are notably ruptured [21].
Information about the relationship between PPE and HIV/
AIDS in India is limited, although a study in south India found
that PPE was seen in almost 8% of HIV-positive patients
visiting a non-governmental care and treatment center [17].
In a recent study, 22.5% of newly diagnosed HIV-positive
patients visiting a governmental tertiary-care hospital in
Jagdalpur were found to have PPE [23]. The prevalence of
EF in HIV-positive individuals also varies widely; it was
observed in 3.1% of HIV-positive patients in Mumbai in one
study and in 11.7% of infected individuals in Bangkok [19,24].
We performed a case-control study in a tertiary-care
government hospital in south India to better describe HIV-
positive patients with PPE and to identify potential risk
factors for PPE in HIV-positive patients seeking services there.
We describe the histology of PPE lesions, and compare the
HIV profiles as well as environmental risk factors in PPE cases
versus non-PPE controls.
Methods
This study consisted of two phases. In the first phase, we
recruited HIV-positive patients with PPE and performed a
cross-sectional, descriptive study to determine the preva-
lence and etiology of PPE in HIV-positive patients. In the
second phase, we recruited HIV-positive patients without
PPE, and we compared them to the previously recruited HIV-
positive patients with PPE to assess risk factors that may be
associated with this skin disease.
The study was performed at the Government Hospital of
Thoracic Medicine (GHTM), a tertiary care hospital in
Chennai, India. GHTM is India’s largest publicly supported
HIV care and treatment facility center. GHTM has been
providing HIV/AIDS care since 1990 and ARV therapy since
Table 1. Questionnaire administered to all subjects in their preferred language
Questionnaire
Screening question: Are you currently experiencing a skin problem of greater than one month duration?
Environmental exposure(s)
I. Do you have animals? If yes, what type?
II. Do you use: 1. mosquito netting; 2. insect repellents; 3. insect coils?
Other exposure(s)
I. Do you live in an urban or rural area?
II. What is your main occupation?
III. Does this work occur mostly indoors or outdoors?
IV. At what time of day do you work?
Arthropod exposure
I. How many bug bites do you see on your skin on a daily basis?
II. What do you think normally bites you?
Prior skin disease history
I. Have you had any prior skin problems, including eczema, psoriasis, scabies, or a skin reaction to medicines or drugs?
Figure 1. Skin biopsy showing fibrin in the stratum corneum, an
intraepidermal vesicle, and a perivascular and interstitial dermal
infiltrate (H&E, 40).
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22004, and it is recognized for its care and treatment of
people living with HIV and AIDS. An estimated 300500 HIV-
positive patients visit GHTM each day for HIV-related care,
treatment, and counseling.
This study was carried out with approval from institutional
review boards at the University of California, San Francisco
(UCSF), and GHTM. All subjects were provided information
from a trained study investigator about the methodology,
information to be collected, potential risks, and purpose of
the study in their preferred language (Tamil, English, or
Telugu). After counseling and prior to enrollment, each
patient provided written consent to be part of the study.
Verbal consent was obtained for taking photographs and for
clinical use as well as study purposes. All records were
entered into a secure, electronic database (Epi Info v. 3.5.1
[Centers for Disease Control and Prevention]) for analysis.
Part I
Patient screening and enrollment were carried out over a
12-week period from April to June 2008. Known HIV-positive,
ARV-naı ¨ve patients, 18 years of age and older, who werebeing
evaluatedbytrainedhospitalstaffatGHTMaspartofstandard
HIV-related services, were queried regarding pruritic rash
originating on extremities for a duration longer than one
month. If they met these criteria, they were examined by an
Indian-trained dermatologist for clinical confirmation of PPE
and a 4.0mm punch biopsy was taken from a skin lesion that
both the patient and the dermatologist identified as the
newest and most representative lesion of PPE. Specimens
were prepared in New Delhi and sent to the All India Institute
of Medical Sciences (AIIMS), New Delhi. Histologic slides were
read by an Indian-trained dermatopathologist with previous
experience in HIV dermatopathology, including PPE. The
dermatopathologist was blinded to the on-site clinical diag-
noses. Subjects included as cases were those who met clinical
criteria for PPE with histologic confirmation. Histologic con-
firmation of PPE was defined as a moderately dense to dense,
superficial and deep, perivascular and interstitial infiltrate of
lymphocytes and eosinophils beneath the epidermis, consis-
tentwith‘‘insectbitereaction.’’Serialsectionswereexamined
to exclude a folliculocentric pathologic process, including EF.
Rash severity was evaluated using an objective ‘‘rash-
severity scale’’ for PPE that was created for this study. Lesions
that were limited to either the upper or lower extremities
were described as ‘‘mild.’’ When both the upper and lower
extremities were involved, the rash was categorized as
‘‘moderate’’disease. A‘‘severe’’ rash included lesions present
ontheextremitiesaswellasthetrunk.Lesionspresentallover
the body, including the face, were defined as ‘‘very severe.’’
In order to assess for potential risk factors, subjects
meeting inclusion criteria were administered an oral and
detailed questionnaire in their preferred language (Tamil,
Telugu, or English) by trained clinicians. The questionnaire
included items assessing the history of the rash, environ-
mental and other types of exposures, and prior history of skin
disorders (Table 1).
Routinely collected demographic and clinical data from the
electronic THIS (TB and HIV Information System) database at
GTHM were obtained for each subject with regard to
immunologic status, which included WHO status, CD4 count,
and date of HIV diagnosis. The THIS electronic patient
Figure 2. Spongiotic intraepidermal vesicle with an underlying
perivascular and interstitial dermal infiltrate (H&E, 100).
Figure 3. Fibrin and eosinophils are seen within the intraepider-
mal vesicle (H&E, 400).
Figure 4. Eosinophils are prominent in the dermal infiltrate (H&E,
400).
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3database was implemented in 2001 at GHTM and collects
routine and longitudinal data for patients during each visit to
the facility using a unique patient identification number that
is generated at the initial patient visit. This secure system
stores and maintains patient data and can be accessed to
inform patient care as well as to generate program-level
reporting to the facility and other stakeholders.
Part II
To identify potential risk factors related to PPE, we recruited
a control group, which included known HIV-positive, ARV-
naı ¨ve patients older than 18 years of age, who did not have
an active skin rash at the time of screening. Patients who
reported experiencing skin lesions or pruritis, or who had any
evidence of skin lesions on clinical exam, were excluded from
this part of the study. Patient screening and enrollment were
carried out over a one-week period in October 2008. After
the same consent process as described in the ‘‘Part I’’ section
was performed by trained hospital staff, the same ques-
tionnaire discussed in ‘‘Part I’’ was orally administered in the
patient’s preferred language (Table 1).
Statistical analysis
We performed statistical analysis using Epi Info version 3.5.1
and SPSS version 11.0 (SPSS Inc., Chicago, IL). Similar data
were collected for both the PPE subjects and the control
populations. Unique outcome measures included the histo-
logical characteristics of new pruritic lesions in the study
population. Categorical variables such as gender, urban
versus rural residence, occupation, treatment history, CD4
count, use of insect repellents, and environmental exposures
were evaluated using the x
2 test (or the Fisher exact test
when an expected value for a category was less than 5). The
t-test was used to evaluate differences in age and the
duration since HIV diagnosis. The Mann-Whitney test was
used to compare non-normally distributed values such as
CD4 cell count. A p-value of less than 0.05 was considered to
be statistically significant.
Results
From April to June 2008, a total of 52 subjects who self-
reported a pruritic skin eruption for longer than one month
duration, with a clinical exam consistent with PPE, were
recruited from both the outpatient and inpatient populations
at GHTM. Of these 52 patients, 42 (79.2%) were found to
have histologically confirmed PPE, and they were included in
our final analysis (Figures 14).
This represented 2.9% of all patients screened (n1466)
during this time period at GHTM. The remaining biopsies
were consistent with other histologic diagnoses (Table 2).
Using the rash severity scale created for this study,
patients with PPE were described as having a mild (n1
[1.9%]), moderate (n16 [30.8%]), severe (n29 [55.8%]),
or very severe (n6 [11.5%]) rash. Increasing rash severity
was associated with lower CD4 cell counts, but this trend was
not statistically significant (p0.7). The majority (n34,
66%) of confirmed PPE cases had a CD4 cell count less than
350 cells/mL.
During the second phase of the study, 149 patients were
screened and enrolled as controls during a one-week period
in October 2008. A comparison of demographic character-
istics amongst the confirmed PPE cases (n42) versus the
controls (n149) resulted in no difference between the two
groups, including age and sex (Table 3).
The difference in the number of females amongst the two
groups was not significant (cases 69% vs. controls 57.7%;
p0.185), and there was no statistical difference within the
proportion of cases versus controls who live in a rural setting
(n25, 59.5% vs. n86, 57.7%; p0.834). In addition,
there was no significant difference in the duration since HIV
diagnosis between the two groups (2.3 years, SD 735.5 vs.
1.9 years, SD 1.9; p0.28). Subjects with PPE, however, had
significantly lower CD4 cell counts in comparison to the
controls (median, 225.5 cells/mL [interquartile range, or IQR:
105.5490.3 cells/mL] vs. 425 cells/mL [IQR, 212641 cells/
mL]; p0.0001).
We compared environmental exposures amongst the PPE
cases versus the controls, and found similar findings for
history of mosquito bites, use of mosquito netting, exposure
to animals, and work outdoors (Table 4).
Patients with PPE, however, were less likely to use insect
repellents, coils, and/or sprays in comparison to controls.
Discussion
In the 1466 routinely evaluated HIV-positive patients at
GHTM, we histologically confirmed PPE in 42 individuals
(2.9%). EF, in comparison, is slightly higher in prevalence
[19,24]. Of patients who presented with bilateral, symmetric,
pruritic papules on the extremities for more than one month
duration (n52), 42 (79.2%) had histologic confirmation of
Table 2. Skin biopsy findings in enrolled subjects (total n52), classified by type of reaction and analyzed by gender (Fisher’s exact
text 0.154)
Sex
Biopsy findings Female n (%) Male n (%) n (%)
Arthropod bite reaction 29 (82.9) 13 (72.2) 42 (79.2)
Psoriasiform 3 (8.6) 0 (0) 3 (5.7)
Granulomatous 1 (2.9) 1 (5.6) 2 (3.8)
Excoriation 0 (0) 1 (5.6) 1 (1.9)
Spongiotic dermatitis 1 (2.9) 0 (0) 1 (1.9)
Non-diagnostic 1 (2.9) 2 (66.7) 3 (5.7)
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4PPE. This revalidation of the criteria used in the 2004
Ugandan PPE study indicates that we may use this clinical
scenario as a screening technique in the diagnosis of PPE.
Using the rash severity scale, the severity of skin rash was
not significantly associated with the CD4 count. This is a
somewhat different result from those of previous studies and
implies that we cannot use rash distribution or severity as an
indicator of CD4 count.
CD4 counts in our PPE study population are higher on
average than what has been previously reported [57]. This
may be related to patients presenting to GHTM for HIV care
at earlier stages of the disease. GHTM has been providing HIV
testing, care, outreach, and treatment to patients in India
since 2004. Given this history, patients with HIV may present
earlier after initial infection with HIV and prior to the
development of severe HIV/AIDS. While CD4 counts in our
case population were higher than previously reported [57],
the majority were still less than CD4 counts of 350 cells/mL.
European and US guidelines have recommended that ARV
therapy be initiated in HIV-positive patients with CD4 counts
less than 350 cells/mL [24].
No studies to date have examined potential PPE-associated
risk factors in HIV-positive persons affected with PPE in
comparison to a control group. This study attempted to
describe the profile of patients with and without PPE who
were presenting to GHTM from the same areas of India with
similar environmental exposures. Overall, a small percen-
tage of HIV-positive patients presented with PPE. However,
because the skin allows for easy visual diagnoses, PPE may be
considered a surrogate marker of immunosuppression and an
indicator for the need to initiate ARV therapy in resource-
poor settings where CD4 count cannot be assessed.
In addition, protective measures against mosquito bites
such as repellents, sprays, and coils appeared to be im-
portant in preventing PPE in subjects at risk. Increased
advocacy, availability, and use may lower the disease burden.
Mosquito netting did not seem to play a role, although it is
not commonly used in India so its actual impact is difficult
to accurately determine through this study. This may be
explained by the fact that subjects are being bitten through-
out the day as well as the evening, and that nets are
protective only against malaria.
Patients living in rural versus urban settings were not
found to have any statistically significant difference in their
risk for PPE, but more in-depth surveys of the environment to
include nearby water pools, animals, and topography may
help identify patients who are at risk of exposure to
arthropods. Future studies from other areas where PPE is
prevalent will be helpful in further defining environmental
risk factors. Treatment options, response to ARV therapy,
outcome in PPE patients, and recurrent PPE during ARV
treatment are areas that require additional study. Genetic
polymorphisms may also be an area of future study to
explain why certain HIV-positive patients develop PPE while
others do not.
Of note, cases and controls were collected at different
times, and therefore the effect of seasonal variation needs to
be considered in this study. Controls were collected during
the early phases of the rainy season (i.e. November) when
there are potentially more insects, representing a bias toward
controls having more PPE versus cases. The reverse was true
in our study. However, it could be argued that subjects
may have taken greater protective measures against being
affected by arthropod bites during the rainy season (e.g. slept
Table 3. Demographic characteristics of subjects enrolled in the study
a
Characteristic PPE cases (n42) Controls (n149) p
Age, mean years (SD) 34.2 (7.5) 33.4 (7.7) 0.57
Female, number (%) 29 (69.0) 86 (57.7) 0.185
Rural residence, number (%) 25 (59.5) 86 (57.7) 0.834
Time since HIV diagnosis, mean days (SD) 834.4 (735.5) 699.5 (685.7) 0.28
Median CD4, most recent (interquartile range) 225.5 (105.5490.3) 425 (212.0641.0) B0.000
Patients receiving CTZ, number (%) 38 (90.4) 148 (99.3) 0.002
aCharacteristics of study participants: PPE are cases defined as adults experiencing a pruritic skin eruption for longer than one month duration,
with evidence of multiple papular or nodular lesions and a skin biopsy indicating an ‘‘insect bite reaction.’’ Controls are defined as adults with no
active skin rash.
Table 4. Comparison of environmental exposures amongst PPE cases and controls
Exposure Cases (n42) Controls (n149) Odds ratio, 95% CI
Female, number (%) 29 (69.05) 86 (57.72) 1.63, 0.793.39
History of mosquito bites, number (%) 34 (81.0) 131 (87.9) 0.584, 0.231.46
Use of mosquito netting, number (%) 5 (11.9) 27 (18.1) 0.61, 0.21.70
Exposure to animals, number (%) 11 (26.2) 47 (31.5) 0.77, 0.361.70
Work outdoors, number (%) 20 (50.0) 62 (41.9) 0.72, 0.361.50
Non-usage of insect repellent, coils, or spray, number (%) 29 (69.0) 64 (43.0) 2.96, 1.436.15
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5under mosquito netting, worn protective spray, or use lighted
antimosquito coils), resulting in a lower exposure to such
arthropods.
Conclusions
In conclusion, the majority of biopsies in persons who
presented with bilateral, symmetric, pruritic papules on the
extremities with duration longer than one month showed
histology consistent with confirmed PPE. In addition, this
finding was associated with CD4 counts lower than 350 cells/
mL, at which point ARV treatment initiation is recommended
as per international standards [25]. PPE may therefore be
used as a marker for initiating therapy in resource-poor
settings. Environmental factors are still to be elucidated, but
protective measures against mosquito bites such as the use
of mosquito coils appeared to be beneficial against develop-
ing PPE.
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